Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

Патология пищеварительного тракта и печени при COVID-19

https://doi.org/10.31146/1682-8658-ecg-176-4-19-23

Полный текст:

Аннотация

Поражение желудочно-кишечного тракта и печени выявляется у более половины пациентов с COVID-19. При этом заболевание может начинаться с гастроэнтерологических проявлений, к которым впоследствии присоединяются респираторные симптомы. Наличие поражений желудочно-кишечного тракта и печени у больных COVID-19 ухудшает прогноз заболевания и повышает риск смертности. Механизмы повреждения пищеварительной системы многообразны: прямой цитолитический эффект вируса на клетки–мишени, на поверхности которых имеются рецепторы для SARS-CoV-2, действие компонентов системного воспаления, иммунологические и лекарственные повреждения. В терапии больных COVID-19 с гастроэнтерологическими расстройствами и нарушением функции печени перспективным направлением является исследование ребамипида и урсодеоксихолевой кислоты.

Об авторах

Э. П. Яковенко
ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России
Россия
профессор кафедры гастроэнтерологии и диетологии ФДПО, д. м. н.

Москва


А. В. Яковенко
ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России
Россия
доцент кафедры гастроэнтерологии и диетологии ФДПО, к. м. н.

Москва


А. Н. Иванов
ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России
Россия
доцент кафедры гастроэнтерологии и диетологии ФДПО, к. м. н.

Москва


Н. А. Агафонова
ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России
Россия
доцент кафедры гастроэнтерологии и диетологии ФДПО, к. м. н.

Москва


Список литературы

1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020;323(8):709–710.

2. Wu Y, Ho W, Huang Y, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet. 2020; Mar 21;395(10228):949–950.

3. Markus Hoffmann et al.SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181, 1–10.

4. Hao Xu1, Liang Zhong1, Jiaxin Denget al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International Journal of Oral Science. 2020; 12:8.

5. Wang К, Chen W., Zhou Y-S.et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. doi: https://doi.org/10.1101/2020.03.14.988345.

6. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; Mar;579(7798):270–273.

7. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.

8. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. https://www.naturalnews.com/fi les/Clinical-characteristics-of-2019-novel-coronavirus-infection-in-China.pdf.

9. Wang F-S, Zhang C. What to do next to control the 2019-nCoV epidemic? Lancet 2020; 395: 391–93.

10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

11. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; Mar 5;382(10):929–936.

12. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva [published on February 12, 2020]. Clin Infect Dis. 2020 Feb 12: ciaa149.

13. Han, C., Duan С., Zhang S. Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. https://journals.lww.com/ajg/Documents/COVID19_Han_et_al_AJG_Preproof.pdf.

14. Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission, Gastroenterology (2020), doi: https://doi.org/10.1053/j.gastro.2020.02.054.

15. Chai X, Hu L, Zhang Y et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv 2020 February 4. doi: 10.1101/2020.02.03.931766.

16. Cai Q, Huang D, Yu H. et al. Characteristics of liver tests in COVID-19 patients, Journal of Hepatology (2020), doi: https://doi.org/10.1016/j.jhep.2020.04.006.

17. Fan Z, Chen L, Li J, et al. Clinical features of COVID-19 related liver damage. MedRxiv 2020 February 28. doi: 10.1101/2020.02.26.20026971. [Epub ahead of print].

18. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020 March 14. doi: 10.1111/liv.14435. [Epub ahead of print].

19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062.

20. Boettler T., Newsome P. N., Mondelli M. U. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper. https://doi.org/10.1016/j.jhepr.2020.100113

21. Xiao F, Tang M, Zheng X et al. Evidence for gastrointestinal infection of SARS-CoV-2, Gastroenterology (2020), https://doi.org/10.1053/j.gastro.2020.02.055.

22. Zhang H, Kang ZJ, Gong HY, et al. The digestive system is a potential route of 2019-n Cov infection: a bioinformatics analysis based on single-cell transcriptomes. Preprint. Posted. online January 30, 2020. bioRxiv 927806. doi: 10.1101/2020.01.30.927806.

23. Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017;15:55–63.

24. He Y, Wen Q, Yao F, Xu D, Huang Y, Wang J. Gut-lung axis: The microbial contributions and clinical implications. Crit Rev Microbiol. 2017;43:81–95.

25. Li M, Wang B, Zhang M, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A. 2008;105:2117–22.

26. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; published online March 4. https://www.researchgate.net/publication/339783197_Liver_injury_in_COVID-19_management_and_challenges.

27. Liu Q, Wang R, Qu G et al. Macroscopic autopsy findings in a patient with COVID-19. J Forensic Med 2020; 36: 1–3 (in Chinese).

28. Arakawa T, Higuchi K, Fujiwara Y et al. 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications. Dig Dis Sci. 2005; 50(1): S3-S11. doi:10.1007/s10620–005–2800–9.

29. Genta R. M. Review article: the role of rebamipide in the management of infl ammatory disease of the gastrointestinal tract Aliment Pharmacol Ther 2003; 18 (Suppl. 1): 8–13.

30. Urita, Yoshihisa & Watanabe, et al. Rebamipide Improves Salivary Gland Function and Saliva Transit to the Distal Esophagus: 48. American Journal of Gastroenterology. 2007. 102. S135. doi:10.14309/00000434–200709002–00048.

31. Lee SY et al. The inhibitory effects of rebamipide on cigarette smoke-induced airway mucin production. Respir Med. 2006 Mar;100(3):503–11.

32. Gohil P et al. Preliminary studies on the effect of rebamipide against the trypsin and egg-albumin induced experimental model of asthma. Acta Pharm. 2011 Dec;61(4):427–33.

33. Ling Xu Jia Liu Mengji Lu et al. Liver injury during highly pathogenic human coronavirus infections Liver International. 2020;00:1–7. doi.org/10.1111/liv.14435.

34. Fangfang Niu et al. Ursodeoxycholic Acid Stimulates Alveolar Fluid Clearance in LPS-induced Pulmonary Edema via ALX/cAMP/PI3K Pathway J Cell Physiol. 2019 Nov;234(11):20057–20065.

35. Willart MA van Nimwegen M, Gref horst A, et al. Ursodeoxycholic acid suppresses eosinophilic airway infl ammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. Allergy. 2012 Dec;67(12):1501–10. doi: 10.1111/all.12019. Epub 2012 Sep 25.


Для цитирования:


Яковенко Э.П., Яковенко А.В., Иванов А.Н., Агафонова Н.А. Патология пищеварительного тракта и печени при COVID-19. Экспериментальная и клиническая гастроэнтерология. 2020;174(4):19-23. https://doi.org/10.31146/1682-8658-ecg-176-4-19-23

For citation:


Yakovenko E.P., Yakovenko A.V., Ivanov A.N., Agafonova N.A. Pathology of the digestive tract and liver with COVID-19. Experimental and Clinical Gastroenterology. 2020;174(4):19-23. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-176-4-19-23

Просмотров: 24


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)